{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T13:04:46Z","timestamp":1773061486357,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T00:00:00Z","timestamp":1564012800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001203","name":"GlaxoSmithKline Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001203","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004963","name":"Seventh Framework Programme","doi-asserted-by":"publisher","award":["FP7\/2007-2013"],"award-info":[{"award-number":["FP7\/2007-2013"]}],"id":[{"id":"10.13039\/501100004963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["115557"],"award-info":[{"award-number":["115557"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.vaccine.2019.07.081","type":"journal-article","created":{"date-parts":[[2019,11,2]],"date-time":"2019-11-02T01:49:54Z","timestamp":1572659394000},"page":"B1-B7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"S2","title":["Why we need more collaboration in Europe to enhance post-marketing surveillance of vaccines"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1360-2388","authenticated-orcid":false,"given":"Miriam","family":"Sturkenboom","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priya","family":"Bahri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Chiucchiuini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tyra","family":"Grove Krause","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Hahn\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alena","family":"Khromava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarit","family":"Kokki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Kramarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Kurz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi J.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"de Lusignan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Mahy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Torcel-Pagnon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Titievsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Bauchau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.07.081_b0005","series-title":"Plotkin's vaccines","article-title":"Chapter 1: a short history of vaccination","author":"Plotkin","year":"2018"},{"key":"10.1016\/j.vaccine.2019.07.081_b0010","unstructured":"World Health Organisation. Vaccine safety basics - elearning course. Module 1: History of vaccine development 2018 [Last accessed 15 May 2018]. Available from: http:\/\/vaccine-safety-training.org\/history-of-vaccine-development.html."},{"key":"10.1016\/j.vaccine.2019.07.081_b0015","unstructured":"World Health Organisation. Vaccines and diseases 2018 [Last accessed 15 May 2018]. Available from: http:\/\/www.who.int\/immunization\/diseases\/en\/."},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2019.07.081_b0020","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/1472-698X-9-S1-S2","article-title":"Global immunization: status, progress, challenges and future","volume":"9","author":"Duclos","year":"2009","journal-title":"BMC Int Health Human Rights"},{"key":"10.1016\/j.vaccine.2019.07.081_b0025","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2471\/BLT.07.040089","article-title":"Vaccination greatly reduces disease, disability, death and inequity worldwide","volume":"86","author":"Andre","year":"2008","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2019.07.081_b0030","series-title":"Plotkin's vaccinese1","article-title":"Chapter 80: regulation of vaccines in Europe","author":"Ehmann","year":"2018"},{"key":"10.1016\/j.vaccine.2019.07.081_b0035","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1016\/j.vaccine.2017.07.061","article-title":"The benefit of the doubt or doubts over benefits? A systematic literature review of perceived risks of vaccines in European populations","volume":"35","author":"Karafillakis","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.081_b0040","doi-asserted-by":"crossref","first-page":"E199","DOI":"10.1503\/cmaj.109-3179","article-title":"Lancet retracts 12-year-old article linking autism to MMR vaccines","volume":"182","author":"Eggertson","year":"2010","journal-title":"CMAJ"},{"key":"10.1016\/j.vaccine.2019.07.081_b0045","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.ebiom.2015.06.018","article-title":"Vaccine hesitancy among general practitioners and its determinants during controversies: a national cross-sectional survey in France","volume":"2","author":"Verger","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2019.07.081_b0050","doi-asserted-by":"crossref","first-page":"6700","DOI":"10.1016\/j.vaccine.2016.10.042","article-title":"Vaccine hesitancy and healthcare providers","volume":"34","author":"Paterson","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.081_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2016.08.042","article-title":"The state of vaccine confidence 2016: global insights through a 67-country survey","author":"Larson","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2019.07.081_b0060","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1016\/j.vaccine.2018.03.063","article-title":"Vaccine hesitancy around the globe: analysis of three years of WHO\/UNICEF joint reporting form data-2015-2017","volume":"36","author":"Lane","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.081_b0065","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12916-017-0850-4","article-title":"Application of real-time global media monitoring and 'derived questions' for enhancing communication by regulatory bodies: the case of human papillomavirus vaccines","volume":"15","author":"Bahri","year":"2017","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2019.07.081_b0070","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1186\/1471-2458-12-938","article-title":"Barriers to pandemic influenza vaccination and uptake of seasonal influenza vaccine in the post-pandemic season in Germany","volume":"12","author":"Bohmer","year":"2012","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2019.07.081_b0075","first-page":"93","article-title":"From the struggle for freedom to the denial of evidence: history of the anti-vaccination movements in Europe","volume":"23","author":"Tafuri","year":"2011","journal-title":"Ann Ig"},{"key":"10.1016\/j.vaccine.2019.07.081_b0080","unstructured":"Valentiner-Branth P. Prevention and control of HPV and HPV related cancers: the Danish experience; 2018 [Last accessed 15 May 2018]. Available from: https:\/\/www.ages.at\/download\/0\/0\/a00df22e71ad1b6ab84022774280e7e28c632fa3\/fileadmin\/AGES2015\/Service\/AGES-Akademie\/2018-01-17_ASM_New_Year_s_Lecture_2018\/HPV_denmark_vienna.pdf."},{"key":"10.1016\/j.vaccine.2019.07.081_b0085","unstructured":"World Health Organisation. Measles outbreaks across Europe threaten progress towards elimination 2017 [Last accessed 18 June 2018]. Available from: http:\/\/www.euro.who.int\/en\/media-centre\/sections\/press-releases\/2017\/measles-outbreaks-across-europe-threaten-progress-towards-elimination."},{"key":"10.1016\/j.vaccine.2019.07.081_b0090","unstructured":"European Centre for Disease Prevention and Control (ECDC). Measles outbreaks still ongoing in 2018 and fatalities reported from four countries 2018 [Last accessed 18 June 2018]. Available from: https:\/\/ecdc.europa.eu\/en\/news-events\/measles-outbreaks-still-ongoing-2018-and-fatalities-reported-four-countries."},{"key":"10.1016\/j.vaccine.2019.07.081_b0095","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.vaccine.2012.12.015","article-title":"The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns","volume":"31","author":"Wijnans","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.081_b0100","series-title":"Research strategies for assessing adverse events associated with vaccines: A workshop summary","author":"Institute of Medicine","year":"1994"},{"key":"10.1016\/j.vaccine.2019.07.081_b0105","unstructured":"European Medicines Agency. EudraVigilance system overview 2017 [Last accessed 6 June 2018]. Available from: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/regulation\/q_and_a\/q_and_a_detail_000166.jsp."},{"key":"10.1016\/j.vaccine.2019.07.081_b0110","unstructured":"Vaccine adverse event reporting system. About VAERS: background and public health Importance 1990 [Last accessed 6 June 2018]. Available from: https:\/\/vaers.hhs.gov\/about.html."},{"key":"10.1016\/j.vaccine.2019.07.081_b0115","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the vaccine adverse event reporting system (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.081_b0120","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1542\/peds.99.6.765","article-title":"Vaccine safety datalink project: a new tool for improving vaccine safety monitoring in the United States. Vaccine Safety Datalink Team","volume":"99","author":"Chen","year":"1997","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2019.07.081_b0125","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/pds.613","article-title":"The vaccine safety datalink project","volume":"10","author":"DeStefano","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2019.07.081_b0130","unstructured":"The Sentinel System 2018 [Last accessed 15 May 2018]. Available from: https:\/\/www.sentinelinitiative.org\/."},{"key":"10.1016\/j.vaccine.2019.07.081_b0135","unstructured":"Canadian Immunization Research Network 2018 [Last accessed 15 May 2018]. Available from: http:\/\/cirnetwork.ca\/about-us\/."},{"key":"10.1016\/j.vaccine.2019.07.081_b0140","unstructured":"Centres for disease control and prevention. Vaccine Safety Datalink (VSD) 2018 [Last accessed 15 May 2018]. Available from: https:\/\/www.cdc.gov\/vaccinesafety\/ensuringsafety\/monitoring\/vsd\/index.html."},{"key":"10.1016\/j.vaccine.2019.07.081_b0145","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.vaccine.2017.08.043","article-title":"Advancing collaborative vaccine benefits and safety research in Europe via the ADVANCE code of conduct","volume":"36","author":"Sturkenboom","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.081_b0150","unstructured":"European Medicines Agency. Pandemic report and lessons learned. Outcome of the European Medicines Agency's activities during the 2009 (H1N1) flu pandemic. EMA\/221017\/2011 2011 [Last accessed 15 May 2018]. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Report\/2011\/04\/WC500105820.pdf."},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2019.07.081_b0155","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/pds.3968","article-title":"Multi-centre, multi-database studies with common protocols: lessons learnt from the IMI PROTECT project","volume":"25","author":"Klungel","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2019.07.081_b0160","unstructured":"European Medicines Agency. Guideline on good pharmacovigilance practices (GVP). Product- or population-specific considerations: Vaccines for prophylaxis against infectious diseases 2013 [Last accessed 15 May 2018]. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2013\/12\/WC500157839.pdf."},{"key":"10.1016\/j.vaccine.2019.07.081_b0165","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s40264-017-0572-8","article-title":"Promoting and protecting public health: How the European Union pharmacovigilance system works","volume":"40","author":"Santoro","year":"2017","journal-title":"Drug Saf"},{"key":"10.1016\/j.vaccine.2019.07.081_b0170","unstructured":"European network of centres for pharmacoepidemiology and pharmacovigilance (ENCePP). ENCePP Guide on methodological standards in pharmacoepidemiology: 10.2.1. Vaccine safety 2018 [Last accessed 15 May 2018]. Available from: http:\/\/www.encepp.eu\/standards_and_guidances\/methodologicalGuide10_2_1.shtml."},{"key":"10.1016\/j.vaccine.2019.07.081_b0175","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1016\/j.vaccine.2011.04.005","article-title":"Safety monitoring of Influenza A\/H1N1 pandemic vaccines in EudraVigilance","volume":"29","author":"Kurz","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.081_b0180","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(09)61877-8","article-title":"Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines","volume":"374","author":"Black","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.07.081_b0185","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/j.vaccine.2017.02.039","article-title":"The ADVANCE code of conduct for collaborative vaccine studies","volume":"35","author":"Kurz","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.081_b0190","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1016\/j.vaccine.2019.04.073","article-title":"Guidance for the governance of public-private collaborations in vaccine post-marketing settings in Europe","volume":"37","author":"Torcel-Pagnon","year":"2019","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19310023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19310023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:35:45Z","timestamp":1759401345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19310023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":38,"alternative-id":["S0264410X19310023"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.07.081","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Why we need more collaboration in Europe to enhance post-marketing surveillance of vaccines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.07.081","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}